{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Truvada+qd",
    "query": {
      "intervention": "Truvada qd"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 31,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Truvada+qd&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-13T17:19:28.224Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05630755",
      "title": "A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "DOR/ISL",
          "type": "DRUG"
        },
        {
          "name": "BIC/FTC/TAF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to BIC/FTC/TAF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to DOR/ISL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 514,
      "start_date": "2023-02-17",
      "completion_date": "2028-08-04",
      "has_results": true,
      "last_update_posted_date": "2025-11-18",
      "last_synced_at": "2026-09-13T17:19:28.224Z",
      "location_count": 24,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05630755"
    },
    {
      "nct_id": "NCT04585737",
      "title": "Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV I Infection"
      ],
      "interventions": [
        {
          "name": "Dolutegravir / Lamivudine Pill",
          "type": "DRUG"
        },
        {
          "name": "Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Charlotte-Paige Rolle, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 222,
      "start_date": "2020-10-05",
      "completion_date": "2023-08-10",
      "has_results": true,
      "last_update_posted_date": "2024-10-17",
      "last_synced_at": "2026-09-13T17:19:28.224Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04585737"
    },
    {
      "nct_id": "NCT00224445",
      "title": "Boosted Atazanavir and Truvada Given Once-Daily - BATON Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Truvada",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2005-09",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2013-01-10",
      "last_synced_at": "2026-09-13T17:19:28.224Z",
      "location_count": 1,
      "location_summary": "Foster City, California",
      "locations": [
        {
          "city": "Foster City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00224445"
    },
    {
      "nct_id": "NCT00988780",
      "title": "Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Immune Reconstitution Inflammatory Syndrome",
        "HIV",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "maraviroc",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 276,
      "start_date": "2009-12",
      "completion_date": "2013-04",
      "has_results": false,
      "last_update_posted_date": "2012-11-27",
      "last_synced_at": "2026-09-13T17:19:28.224Z",
      "location_count": 4,
      "location_summary": "Bethesda, Maryland • Cleveland, Ohio • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00988780"
    },
    {
      "nct_id": "NCT03836729",
      "title": "Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Tenofovir alafenamide/emtricitabine",
          "type": "DRUG"
        },
        {
          "name": "GSK3640254",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 16,
      "start_date": "2019-02-11",
      "completion_date": "2019-04-30",
      "has_results": true,
      "last_update_posted_date": "2020-04-21",
      "last_synced_at": "2026-09-13T17:19:28.224Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03836729"
    },
    {
      "nct_id": "NCT04564547",
      "title": "Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "Islatravir",
          "type": "DRUG"
        },
        {
          "name": "Ulonivirine",
          "type": "DRUG"
        },
        {
          "name": "BIC/FTC/TAF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to ISL",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Ulonivirine",
          "type": "DRUG"
        },
        {
          "name": "Placebo to BIC/FTC/TAF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 161,
      "start_date": "2021-03-09",
      "completion_date": "2025-01-30",
      "has_results": true,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-09-13T17:19:28.224Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Ft. Pierce, Florida + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04564547"
    },
    {
      "nct_id": "NCT04233879",
      "title": "Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "DOR/ISL",
          "type": "DRUG"
        },
        {
          "name": "BIC/FTC/TAF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to BIC/FTC/TAF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to DOR/ISL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 599,
      "start_date": "2020-02-28",
      "completion_date": "2025-01-29",
      "has_results": true,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-09-13T17:19:28.224Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04233879"
    },
    {
      "nct_id": "NCT06891066",
      "title": "A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Human Immunodeficiency Virus Type 1 (HIV-1) Infection"
      ],
      "interventions": [
        {
          "name": "ISL",
          "type": "DRUG"
        },
        {
          "name": "ULO",
          "type": "DRUG"
        },
        {
          "name": "BIC/FTC/TAF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2025-04-14",
      "completion_date": "2031-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-09-13T17:19:28.224Z",
      "location_count": 11,
      "location_summary": "San Francisco, California • West Hollywood, California • Washington D.C., District of Columbia + 8 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "West Hollywood",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06891066"
    },
    {
      "nct_id": "NCT00775606",
      "title": "Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acquired Immune Deficiency Syndrome"
      ],
      "interventions": [
        {
          "name": "Lopinavir 400 mg/ritonavir 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Efavirenz",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 15,
      "start_date": "2008-10",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2023-05-26",
      "last_synced_at": "2026-09-13T17:19:28.224Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00775606"
    },
    {
      "nct_id": "NCT00552240",
      "title": "Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "tenofovir DF 300 mg QD",
          "type": "DRUG"
        },
        {
          "name": "emtricitabine 200 mg QD",
          "type": "DRUG"
        },
        {
          "name": "Nevirapine 200 mg BID",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir 100 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 154,
      "start_date": "2007-09",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-01-27",
      "last_synced_at": "2026-09-13T17:19:28.224Z",
      "location_count": 19,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Denver, Colorado + 15 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00552240"
    }
  ]
}